| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US6417191 | VIIV HLTHCARE | Synergistic combinations of zidovudine, 1592U89 and 3TC |
Mar, 2016
(8 years ago) | |
| US5905082 | VIIV HLTHCARE | Crystalline oxathiolane derivatives |
May, 2016
(7 years ago) | |
|
US6417191 (Pediatric) | VIIV HLTHCARE | Synergistic combinations of zidovudine, 1592U89 and 3TC |
Sep, 2016
(7 years ago) | |
|
US5905082 (Pediatric) | VIIV HLTHCARE | Crystalline oxathiolane derivatives |
Nov, 2016
(7 years ago) | |
| US6294540 | VIIV HLTHCARE | Carbocyclic nucleoside hemisulfate and its use in treating viral infections |
May, 2018
(5 years ago) | |
|
US6294540 (Pediatric) | VIIV HLTHCARE | Carbocyclic nucleoside hemisulfate and its use in treating viral infections |
Nov, 2018
(5 years ago) | |
Epzicom is owned by Viiv Hlthcare.
Epzicom contains Abacavir Sulfate; Lamivudine.
Epzicom has a total of 6 drug patents out of which 6 drug patents have expired.
Expired drug patents of Epzicom are:
- US6417191
- US5905082
- US6417191*PED
- US5905082*PED
- US6294540
- US6294540*PED
Epzicom was authorised for market use on 02 August, 2004.
Epzicom is available in tablet;oral dosage forms.
Epzicom can be used as treatment of hiv infection.
The generics of Epzicom are possible to be released after 14 November, 2018.
Drugs and Companies using ABACAVIR SULFATE; LAMIVUDINE ingredient
Market Authorisation Date: 02 August, 2004
Treatment: Treatment of hiv infection
Dosage: TABLET;ORAL
How can I launch a generic of EPZICOM before it's drug patent expiration?
More Information on Dosage
EPZICOM family patents
